Next-Generation Sequencing Panel Test in Myeloid Neoplasms and
Evaluation with the Clinical Results

Yuce Kahraman, Cigdem; Tatar, Abdulgani; SİNCAN, gulden

doi:10.5152/eurasianjmed.2022.21102

Next-Generation Sequencing Panel Test in Myeloid Neoplasms and Evaluation with the Clinical Results

Çiğdem YÜCE KAHRAMAN, (Atatürk Üniversitesi Tıp Fakültesi, Tıbbi Genetik Anabilim Dalı, Erzurum, Türkiye)

Abdulgani TATAR, (Atatürk Üniversitesi Tıp Fakültesi, Tıbbi Genetik Anabilim Dalı, Erzurum, Türkiye)

Gülden SİNCAN (Atatürk Üniversitesi Tıp Fakültesi, Hematoloji Anabilim Dalı, Erzurum, Türkiye)

Eurasian Journal of Medicine

4 0

Yıl: 2022 Cilt: 54 Sayı: 2 Sayfa Aralığı: 181 - 185 Metin Dili: İngilizce DOI: 10.5152/eurasianjmed.2022.21102 İndeks Tarihi: 05-07-2022

Next-Generation Sequencing Panel Test in Myeloid Neoplasms and Evaluation with the Clinical Results

Öz:

Objective: Myeloid malignancies are heterogeneous disorders due to defective hematopoiesis and myeloid differentiation of hematopoietic stem/progenitor cell. The molecular landscape of the diseases is complex. Molecular alterations are used for classification and evaluation of prognosis and treatment. We aimed to evaluate the advantages of the next-generation sequencing panel testing in myeloid malignancies and clinical outcomes. Materials and Methods: We evaluated the results of 54 patients who underwent next-generation sequencing myeloid panel testing, with fluorescent in situ hybridization (FISH), polymerase chain reaction results and the clinical outcomes. Target genes in the panel were ASXL1, CALR, CBL, CEBPA, CSF3R, DNMT3A, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NPM1, NRAS, RUNX1, SETBP1, SF3B1, SH2B3, SRSF2, TET2, TP53, U2AF1, and ZRSR2. Results: Diagnoses were acute myeloid leukemia, essential thrombocytosis, polistemia vera, primary myelofibrosis, hypereosinophilic syndrome (HES), chronic myeloid leukemia, myelodysplastic syndromes, chronic myelomonocytic leukemia. Twenty-eight missense, 8 frameshift, 5 stop gain, and 3 in-frame mutations were detected. A double mutation was detected in JAK-2 with next-generation sequencing in the patient who was given a false negative result due to polymerase chain reaction limitation. Conclusion: Screening multiple mutations simultaneously, is time and cost-effective. With the panel test, it is possible to determine the diagnosis, prognosis and targeted treatment options with a single test. Nextgeneration sequencing myeloid panel tests might be a powerful guide for clinicians.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Docking TR, Karan A. Genomic testing in myeloid malignancy. Int J Lab Hematology. 2019;41(supply 1):117-125. [CrossRef]
2. de Rooij JD, Zwaan CM, van den Heuvel- Eibrink M. Pediatric AML: From biology to clinical management. J Clin Med. 2015;4(1):127-149. [CrossRef]
3. Bacher U, Schnittger S, Haferlach C, Haferlach T. Molecular diagnostics in acute leukemias. Clin Chem Lab Med. 2009;47(11):1333-1341. [CrossRef]
4. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5):1532-1542. [CrossRef]
5. Kuo FC, Dong F. Next-generation sequencingbased panel testing for myeloid neoplasms. Curr Hematol Malig Rep. 2015;10(2):104-111. [CrossRef]
6. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447. [CrossRef]
7. Yang F, Anekpuritanang T, Press RD. Clinical utility of next-generation sequencing in acute myeloid leukemia. Mol Diagn Ther. 2020;24(1):1-13. [CrossRef]
8. Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241-247. [CrossRef]
9. Cumbo C, Tota G, Anelli L, Zagaria A, Specchia G, Albano F. TP53 in myelodysplastic syndromes: recent biological and clinical findings. Int J Mol Sci. 2020;21(10). [CrossRef]
10. Malcovati L, Karimi M, Papaemmanuil E, et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood. 2015;126(2):233-241. [CrossRef]
11. Mangaonkar AA, Gangat N, Al-Kali A, et al. Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts. Leuk Res. 2018;71:60-62. [CrossRef]
12. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. [CrossRef]
13. Saeidi K. Myeloproliferative neoplasms: current molecular biology and genetics. Crit Rev Oncol Hematol. 2016;98:375-389. [CrossRef]
14. Skoda RC, Duek A, Grisouard J. Pathogenesis of myeloproliferative neoplasms. Exp Hematol. 2015;43(8):599-608. [CrossRef]
15. Guglielmelli P, Pacilli A, Rotunno G, et al. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood. 2017;129(24):3227-3236. [CrossRef]
16. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424. [CrossRef]
17. Ward AF, Braun BS, Shannon KM. Targeting oncogenic Ras signaling in hematologic malignancies. Blood. 2012;120(17):3397-3406. [CrossRef]
18. DiNardo CD, Cortes JE. Mutations in AML: prognostic and therapeutic implications. Hematology Am Soc Hematol Educ Program 2016;2016(1):348-355. [CrossRef]
19. Zhang TJ, Zhou JD, Yang DQ, et al. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia. J Cell Physiol. 2018;233(8):5838-5846. [CrossRef]
20. Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079-1089. [CrossRef]
21. Alduaij W, McNamara CJ, Schuh A, et al. Clinical utility of next-generation sequencing in the management of myeloproliferative neoplasms: A single-center experience. Hemasphere. 2018;2(3):e44. [CrossRef]
22. Yoo JH, Park TS, Maeng HY, et al. JAK2 V617F/ C618R mutation in a patient with polycythemia vera: a case study and review of the literature. Cancer Genet Cytogenet. 2009;189(1):43-47. [CrossRef]
23. Karow A, Waller C, Reimann C, Niemeyer CM, Kratz CP. JAK2 mutations other than V617F: a novel mutation and mini review. Leuk Res. 2008;32(2):365-366. [CrossRef]
24. Ma W, Kantarjian H, Zhang X, et al. Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. J Mol Diagn. 2009;11(1):49-53. [CrossRef]
25. Tiong IS, Casolari DA, Moore S, et al. Apparent ‘JAK2-negative’ polycythaemia vera due to compound mutations in exon 14. Br J Haematol. 2017;178(2):333-336. [CrossRef]
26. Kang MG, Choi HW, Lee JH, et al. Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia. Oncotarget. 2016;7(35):57036-57049. [CrossRef]
27. Asp J, Andréasson B, Hansson U, et al. Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome. Haematologica. 2016;101(4):e129-e132. [CrossRef]
28. Solary E. Chronic Myelomonocytic Leukemia (CMML). Atlas Genet Cytogenet Oncol Haematol. 2014;18(1):50-52.

APA	Yuce Kahraman C, Tatar A, SİNCAN g (2022). Next-Generation Sequencing Panel Test in Myeloid Neoplasms and Evaluation with the Clinical Results. , 181 - 185. 10.5152/eurasianjmed.2022.21102
Chicago	Yuce Kahraman Cigdem,Tatar Abdulgani,SİNCAN gulden Next-Generation Sequencing Panel Test in Myeloid Neoplasms and Evaluation with the Clinical Results. (2022): 181 - 185. 10.5152/eurasianjmed.2022.21102
MLA	Yuce Kahraman Cigdem,Tatar Abdulgani,SİNCAN gulden Next-Generation Sequencing Panel Test in Myeloid Neoplasms and Evaluation with the Clinical Results. , 2022, ss.181 - 185. 10.5152/eurasianjmed.2022.21102
AMA	Yuce Kahraman C,Tatar A,SİNCAN g Next-Generation Sequencing Panel Test in Myeloid Neoplasms and Evaluation with the Clinical Results. . 2022; 181 - 185. 10.5152/eurasianjmed.2022.21102
Vancouver	Yuce Kahraman C,Tatar A,SİNCAN g Next-Generation Sequencing Panel Test in Myeloid Neoplasms and Evaluation with the Clinical Results. . 2022; 181 - 185. 10.5152/eurasianjmed.2022.21102
IEEE	Yuce Kahraman C,Tatar A,SİNCAN g "Next-Generation Sequencing Panel Test in Myeloid Neoplasms and Evaluation with the Clinical Results." , ss.181 - 185, 2022. 10.5152/eurasianjmed.2022.21102
ISNAD	Yuce Kahraman, Cigdem vd. "Next-Generation Sequencing Panel Test in Myeloid Neoplasms and Evaluation with the Clinical Results". (2022), 181-185. https://doi.org/10.5152/eurasianjmed.2022.21102

APA	Yuce Kahraman C, Tatar A, SİNCAN g (2022). Next-Generation Sequencing Panel Test in Myeloid Neoplasms and Evaluation with the Clinical Results. Eurasian Journal of Medicine, 54(2), 181 - 185. 10.5152/eurasianjmed.2022.21102
Chicago	Yuce Kahraman Cigdem,Tatar Abdulgani,SİNCAN gulden Next-Generation Sequencing Panel Test in Myeloid Neoplasms and Evaluation with the Clinical Results. Eurasian Journal of Medicine 54, no.2 (2022): 181 - 185. 10.5152/eurasianjmed.2022.21102
MLA	Yuce Kahraman Cigdem,Tatar Abdulgani,SİNCAN gulden Next-Generation Sequencing Panel Test in Myeloid Neoplasms and Evaluation with the Clinical Results. Eurasian Journal of Medicine, vol.54, no.2, 2022, ss.181 - 185. 10.5152/eurasianjmed.2022.21102
AMA	Yuce Kahraman C,Tatar A,SİNCAN g Next-Generation Sequencing Panel Test in Myeloid Neoplasms and Evaluation with the Clinical Results. Eurasian Journal of Medicine. 2022; 54(2): 181 - 185. 10.5152/eurasianjmed.2022.21102
Vancouver	Yuce Kahraman C,Tatar A,SİNCAN g Next-Generation Sequencing Panel Test in Myeloid Neoplasms and Evaluation with the Clinical Results. Eurasian Journal of Medicine. 2022; 54(2): 181 - 185. 10.5152/eurasianjmed.2022.21102
IEEE	Yuce Kahraman C,Tatar A,SİNCAN g "Next-Generation Sequencing Panel Test in Myeloid Neoplasms and Evaluation with the Clinical Results." Eurasian Journal of Medicine, 54, ss.181 - 185, 2022. 10.5152/eurasianjmed.2022.21102
ISNAD	Yuce Kahraman, Cigdem vd. "Next-Generation Sequencing Panel Test in Myeloid Neoplasms and Evaluation with the Clinical Results". Eurasian Journal of Medicine 54/2 (2022), 181-185. https://doi.org/10.5152/eurasianjmed.2022.21102